List view / Grid view
Researchers at NYU Abu Dhabi have developed a cheap, paper-based platform that allows tumour models to be grown, frozen and stored for future cancer drug testing – called Spheromatrix.
Protein folding interference offers access to targets long considered unreachable by traditional drug discovery. By acting on transient folding intermediates, this approach presents a new opportunity to eliminate disease-driving proteins.
Vortex Liquid Biopsy Solutions has launched a new clinical study with The Doctors Laboratory to assess how its live-cell liquid biopsy technology could change cancer monitoring and treatment.
Researchers have discovered how to inhibit the P2X4 receptor, a key protein linked to chronic pain, inflammation and certain cancers.
Scientists have developed an organ-on-a-chip platform that replicates age-related immune decline, offering a long-missing tool for testing cancer vaccines in older adults.
A new analysis has identified the hormone estrone as a major driver of aggressive breast cancer in post-menopausal women with obesity, meaning that weight-loss drugs could help improve treatment outcomes.
A new collaboration between Crown Bioscience and Medicines Discovery Catapult is bringing advanced tumour models together with world-class imaging and radiochemistry to accelerate the development of next-generation radiopharmaceuticals.
Insilico Medicine has announced ISM3830, an AI-designed CBLB inhibitor that has demonstrated promising preclinical results.
A new study reveals that TIGIT, a key immune checkpoint targeted by cancer drugs, behaves differently in rhesus macaques and humans, suggesting current animal tests may be misleading drug development.
A new study has revealed that many kinase inhibitors – key drugs used in cancer and other diseases – also trigger the accelerated degradation of their target proteins, which could inform future therapies.
Samsung Life Science Fund has made a strategic equity investment in clinical-stage biotechnology company Phrontline Biopharma, supporting the development of next-generation antibody-drug conjugates (ADCs).
Tasca Therapeutics is using chemical proteomics to map lipid-binding pockets on proteins. By targeting auto-palmitoylation, the company aims to turn previously undruggable cancer drivers into viable therapeutic targets.
Researchers have developed a novel CRISPR method that evades the immune system in mice, allowing scientists to study tumour growth and metastasis more accurately.
The UK is set to turn recycled nuclear fuel into new cancer treatments, thanks to a £18.8 million investment in a project using lead-212 to develop Targeted Alpha Therapies.
Scientists have discovered active bacterial traces inside brain tumours, overturning assumptions about the brain’s sterility and opening up new possibilities for understanding – and potentially treating – gliomas and brain metastases.
